Edition:
United States

Biocon Ltd (BION.BO)

BION.BO on Bombay Stock Exchange

263.00INR
1:29am EDT
Change (% chg)

Rs0.20 (+0.08%)
Prev Close
Rs262.80
Open
Rs264.00
Day's High
Rs264.25
Day's Low
Rs260.45
Volume
61,791
Avg. Vol
222,491
52-wk High
Rs359.17
52-wk Low
Rs230.00

Latest Key Developments (Source: Significant Developments)

Biocon Gets Certificate Of GMP Compliance For Bengaluru Facilities
Friday, 14 Jun 2019 04:41am EDT 

June 14 (Reuters) - Biocon Ltd ::BIOCON-GETS CERTIFICATE OF GMP COMPLIANCE FROM EMA FOR BIOLOGICS DRUG PRODUCT AND DRUG SUBSTANCE FACILITIES IN BENGALURU.  Full Article

India's Biocon March Quarter Consol Profit Rises
Friday, 24 May 2019 10:33am EDT 

May 24 (Reuters) - Biocon Ltd ::MARCH QUARTER CONSOL PROFIT 2.14 BILLION RUPEES VERSUS PROFIT OF 1.30 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL PROFIT WAS 2.01 BILLION RUPEES.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 15.29 BILLION RUPEES VERSUS 11.70 BILLION RUPEES LAST YEAR.  Full Article

Biocon Says Health Canada Approved Co And Mylan's Cancer Drug
Wednesday, 22 May 2019 09:02am EDT 

May 22 (Reuters) - Biocon Ltd ::HEALTH CANADA APPROVES BIOCON AND MYLAN'S OGIVRI™, FIRST TRASTUZUMAB BIOSIMILAR, FOR TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS.  Full Article

India's Biocon March-Qtr Consol Profit Surges
Thursday, 25 Apr 2019 10:06am EDT 

April 25 (Reuters) - Biocon Ltd ::MARCH QUARTER CONSOL PROFIT 2.14 BILLION RUPEES VERSUS PROFIT OF 1.30 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL PROFIT WAS 2.01 BILLION RUPEES.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 15.29 BILLION RUPEES VERSUS 11.70 BILLION RUPEES LAST YEAR.SAYS - RECOMMENDED THE ISSUE OF BONUS SHARES BY CAPITALISATION OF FREE RESERVES IN THE RATIO OF 1:1.SEEKS SHAREHOLDERS' NOD FOR RE-APPOINTMENT OF ARUN SURESH CHANDAVARKAR AS CEO & JOINT MANAGING DIRECTOR.  Full Article

Biocon Says Biocon Facilities Complete Pre Approval U.S.FDA Inspection
Sunday, 17 Feb 2019 09:54pm EST 

Feb 18 (Reuters) - Biocon Ltd ::SAYS BIOCON FACILITIES COMPLETE PRE APPROVAL U.S.FDA INSPECTION.BIOCON - THERE WERE NO OBSERVATIONS OND NO FORM 48J WAS ISSUED AFTER THE PRE-APPROVAL INSPECTION OF ORAL SOLID DOSAGE FACILITY.  Full Article

India's Biocon Dec-Qtr Profit Rises
Thursday, 24 Jan 2019 07:00am EST 

Jan 24 (Reuters) - Biocon Ltd ::DEC QUARTER CONSOL PROFIT 2.17 BILLION RUPEES VERSUS PROFIT OF 919 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 1.76 BILLION RUPEES.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 15.41 BILLION RUPEES VERSUS 10.58 BILLION RUPEES LAST YEAR.  Full Article

Biocon Says FDA Issues Zero 483 Observations For Bengaluru Facility
Wednesday, 14 Nov 2018 05:56am EST 

Nov 14 (Reuters) - Biocon Ltd ::BIOCON - U.S. FDA CONDUCTED PRE APPROVAL INSPECTION OF ORAL SOLID DOSAGE FORMS MANUFACTURING FACILITY AT BIOCON PARK/ BENGALURU FROM NOV 05- NOV 09.BIOCON - AUDIT CONCLUDED WITHOUT ANY OBSERVATIONS AND NO FORM 483 WAS ISSUED.  Full Article

Biocon Says European Medicines Agency's CMPH Recommends Approval Of Fulphila
Friday, 21 Sep 2018 09:33am EDT 

Sept 21 (Reuters) - Biocon Ltd ::BIOCON SAYS EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE HAS ISSUED POSITIVE OPINION RECOMMENDING APPROVAL OF FULPHILA.SAYS CHMP POSITIVE OPINION WILL NOW BE CONSIDERED BY THE EUROPEAN COMMISSION.SAYS DECISION ON APPROVAL IS EXPECTED BY NOVEMBER 2018.  Full Article

Biocon Q4 Net Profit Up 2 Percent
Thursday, 26 Apr 2018 10:55am EDT 

April 26 (Reuters) - Biocon Ltd ::Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO.  Full Article

Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU
Wednesday, 11 Apr 2018 07:23am EDT 

April 11 (Reuters) - Biocon Ltd ::MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU.  Full Article

India's Biocon quarterly profit more than doubles, beats estimate

Jan 24 Indian biotechnology firm Biocon Ltd's quarterly profit more than doubled, handily beating analysts' estimates, largely driven by strong performance of its biologics businesses.

No consensus analysis data available.